PQ6 Stock Overview
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Starpharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.073 |
| 52 Week High | AU$0.29 |
| 52 Week Low | AU$0.061 |
| Beta | 0.77 |
| 1 Month Change | 4.26% |
| 3 Month Change | -6.96% |
| 1 Year Change | -74.30% |
| 3 Year Change | -93.19% |
| 5 Year Change | -90.70% |
| Change since IPO | -85.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| PQ6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 16.7% | 2.3% | 0.5% |
| 1Y | -74.3% | -28.6% | 1.3% |
Return vs Industry: PQ6 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: PQ6 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| PQ6 volatility | |
|---|---|
| PQ6 Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PQ6 has not had significant price volatility in the past 3 months.
Volatility Over Time: PQ6's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 45 | Cheryl Maley | starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers.
Starpharma Holdings Limited Fundamentals Summary
| PQ6 fundamental statistics | |
|---|---|
| Market cap | €33.79m |
| Earnings (TTM) | -€5.10m |
| Revenue (TTM) | €6.39m |
5.3x
P/S Ratio-6.6x
P/E RatioIs PQ6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQ6 income statement (TTM) | |
|---|---|
| Revenue | AU$10.52m |
| Cost of Revenue | AU$11.68m |
| Gross Profit | -AU$1.16m |
| Other Expenses | AU$7.24m |
| Earnings | -AU$8.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | -11.02% |
| Net Profit Margin | -79.79% |
| Debt/Equity Ratio | 0% |
How did PQ6 perform over the long term?
See historical performance and comparison